Skip to content
Catalyst

berberineFinding

Berberine decreases aspartate aminotransferase

lowersModerate evidenceFindingreplicated ×1

01 · The sentence it was drawn from

“In 7 RCTs comprising 632 individuals with NAFLD,, berberine demonstrated efficacy in reducing AST levels, showing a remarkable reduction in the enzyme (SMD = − 0.79, 95% CI [− 1.17, − 0.40], P < 0.0001, I2 = 82%; Fig. 4).”
Quoted verbatim from The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review.
This finding among the 50 findings on its endpoint

berberine

Aspartate aminotransferase

lowers

Effect as reported

−0.79standardised mean difference

CI −1.17 to −0.4

Who
n = 632 · Adults with NAFLD in 7 pooled RCTs; berberine added to metformin in both-arm-metformin trials (patients with comorbid diabetes) or compared with lifestyle intervention or placebo
Dose studied
berberine 0.6 g to 2 g daily in 9 RCTs, 6.35 g daily in one; 7 to 24 weeks

Moderate evidencePMID 38429794 · 2024

02 · The study

Study
meta-analysis
Participants
632
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Journal of translational medicine
What else it reported5 findings · 1 compound · 5 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZAE7EPAX90BT63VD3Q96DW